Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Lymphoma | Review

Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

Authors: Bo Wang, Zijian Wang, Lizhi Han, Song Gong, Yanxue Wang, Zhiwen He, Yong Feng, Zhaohui Yang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of malignancy patients. But, its prognostic role of cyclin D3 in neoplasms remains controversial.

Methods

Databases involving EMBASE, PubMed and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing cyclin D3 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of cyclin D3.

Results

There were 13 eligible researches involving 16 cohorts and 2395 participants which were included in this study. The outcomes suggested that highly expressing cyclin D3 was significantly correlated with worse clinical prognosis of overall survival (HR 1.88; 95% CI 1.31–2.69) and disease specific survival (HR 2.68; 95% CI 1.35–5.31). But there existed no significant connection between the elevated expression of cyclin D3 with disease free survival (HR 2.65; 95% CI 0.83–8.46), recurrence-free survival (HR 2.86; 95% CI 0.82–9.96) and progression-free survival (HR 5.24; 95% CI 0.46–60.25) of diffident kinds of malignancy patients. Moreover, we discovered that elevated cyclin D3 expression was significantly connected with decreased overall survival in lymphoma (HR 3.72; 95% CI 2.18–6.36) while no significant relevance between highly expressing cyclin D3 and the overall survival in breast cancer was obtained (HR 2.12; 95% CI 0.76–5.91).

Conclusions

This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.
Literature
1.
2.
Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
3.
Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene. 1998;17(8):1027–37.PubMedCrossRef
4.
Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays News Rev Mol Cell Dev Biol. 2010;19(4):307–15.CrossRef
5.
Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996;8(6):805.PubMedCrossRef
6.
7.
Herzinger T, Reed SI. Cyclin D3 is rate-limiting for the G1/S phase transition in fibroblasts. J Biol Chem. 1998;273(24):14958–61.PubMedCrossRef
8.
Zamani-Ahmadmahmudi M, Aghasharif S, Ilbeigi K. Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart. BMC Vet Res. 2017;13(1):17.PubMedPubMedCentralCrossRef
9.
Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer (Oxford, England : 1990). 2018;91:47–55.CrossRef
10.
Ortiz AB, Garcia D, Vicente Y, Palka M, Bellas C, Martin P. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS ONE. 2017;12(11):e0188068.PubMedPubMedCentralCrossRef
11.
Almangush A, Heikkinen I, Makitie AA, Coletta RD, Laara E, Leivo I, Salo T. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer. 2017;117(6):856–66.PubMedPubMedCentralCrossRef
12.
Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Magliulo G, Presutti L, Re M. The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma. Eur Arch oto-rhino-laryngol. 2016;273(4):801–9.CrossRef
13.
Li Y, Wei J, Xu C, Zhao Z, You T. Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PLoS ONE. 2014;9(4):e94508.PubMedPubMedCentralCrossRef
14.
Zhao J, Li L, Wei S, Gao Y, Chen Y, Wang G, Wu Z. Clinicopathological and prognostic role of cyclin D1 in esophageal squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2012;25(6):520–6.PubMedCrossRef
15.
Zhao Y, Yu D, Li H, Nie P, Zhu Y, Liu S, Zhu M, Fang B. Cyclin D1 overexpression is associated with poor clinicopathological outcome and survival in oral squamous cell carcinoma in Asian populations: insights from a meta-analysis. PLoS ONE. 2014;9(3):e93210.PubMedPubMedCentralCrossRef
16.
Amen F, Horncastle D, Elderfield K, Banham AH, Bower M, Macdonald D, Kanfer E, Naresh KN. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology. 2007;51(1):70–9.PubMedCrossRef
17.
Ko E, Kim Y, Park SE, Cho EY, Han J, Shim YM, Park J, Kim DH. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2012;77(2):401–6.CrossRef
18.
Tsutsui M, Iizuka N, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Fujita Y, Hamamoto Y, Tsunedomi R, et al. Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. Clin Chim Acta Int J Clin Chem. 2010;411(7–8):516–20.CrossRef
19.
Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology. 2013;144(4):799–807.e724.PubMedCrossRef
20.
Xiong Y, Menninger J, Beach D, Ward DC. Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics. 1992;13(3):575–84.PubMedCrossRef
21.
Bartkova J, Zemanova M, Bartek J. Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer. 1996;65(3):323–7.PubMedCrossRef
22.
Draper N, Bui M, Boulware DC, Lloyd M, Chiappori AA, Pledger WJ, Coppola D. Increased cyclin D3 expression significantly correlates with p27 nuclear positivity in gastrointestinal stromal tumors. Hum Pathol. 2008;39(12):1784–91.PubMedCrossRef
23.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 2010;124(9):2077–81.CrossRef
24.
Kim Y, Kim J, Jang SW, Ko J. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer. Oncogene. 2014;34:226.PubMedCrossRef
25.
Müller-Höcker J, Babaryka G, Schmid I, Jung A. Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion. Pathol Res Pract. 2008;204(8):589–97.PubMedCrossRef
26.
Beltran AL, Ordonez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Kirkali Z, Cheng L, Montironi R, Prieto R, et al. Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma. J Biol Regul Homeost Agents. 2013;27(2):559–67.PubMed
27.
Sasaki E, Yatabe Y, Hashimoto M, Yamashita Y, Hasegawa Y, Kojima H, Nagasawa T, Mori N. Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma. Pathol Int. 2007;57(2):53–9.PubMedCrossRef
28.
Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. 2007;60(4):377–81.PubMedCrossRef
29.
Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N. Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res. 2001;21(2a):1043–8.PubMed
30.
Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene. 2008;27(22):3111–21.PubMedCrossRef
31.
Rullo R, Festa VM, Accardo M, Ferraraccio F. The immunohistochemical outline of p27kip1, cyclin B1 and cyclin D3 in pleomorphic adenomas. Minerva Stomatol. 2006;55(9):483–92.PubMed
32.
Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, Lu KH. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer. 2006;16(4):1668–72.PubMedCrossRef
33.
Chen CS, Lee CH, Hsieh CD, Ho CT, Pan MH, Huang CS, Tu SH, Wang YJ, Chen LC, Chang YJ, et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat. 2011;125(1):73–87.PubMedCrossRef
34.
Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung cancer (Amsterdam, Netherlands). 2011;74(3):384–91.CrossRef
35.
Cheng J, Gao J, Shuai X, Tao K. Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a metaanalysis of individual studies. Oncotarget. 2016;7(17):24314–25.PubMedPubMedCentralCrossRef
36.
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10(1):51.PubMedPubMedCentralCrossRef
37.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–91.PubMedPubMedCentralCrossRef
38.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef
39.
Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res. 2002;8(3):729–33.PubMed
40.
41.
Huang B, Li H, Huang L, Luo C, Zhang Y. Clinical significance of microRNA 138 and cyclin D3 in hepatocellular carcinoma. J Surg Res. 2015;193(2):718–23.PubMedCrossRef
42.
Lopez-Beltran A, Requena MJ, Luque RJ, Alvarez-Kindelan J, Quintero A, Blanca AM, Rodriguez ME, Siendones E, Montironi R. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol. 2006;209(1):106–13.PubMedCrossRef
43.
Pruneri G, Pignataro L, Valentini S, Fabris S, Maisonneuve P, Carboni N, Pece S, Capra M, Del Curto B, Neri A, et al. Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res. 2005;11(1):242–8.PubMed
44.
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566–75.PubMedCrossRef
45.
Levidou G, Korkolopoulou P, Thymara I, Vassilopoulos I, Saetta AA, Gakiopoulou H, Konstantinidou A, Kairi-Vassilatou E, Pavlakis K, Patsouris E. Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. Int J gynecol Pathol. 2007;26(4):410–7.PubMedCrossRef
46.
Moller MB, Nielsen O, Pedersen NT. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. Am J Clin Pathol. 2001;115(3):404–12.PubMedCrossRef
47.
Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol. 2004;122(3):444–52.PubMedCrossRef
48.
Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6(9):3614–20.PubMed
49.
Chen BB, Xu XP, Shen L, Han TJ, Lin ZG, Chen Z, Kang H, Huang B, Lin GW. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma. Chin Med J. 2013;126(3):482–7.PubMed
50.
Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol. 2010;5(9):1325–36.PubMedCrossRef
51.
Hedberg Y, Roos G, Ljungberg B, Landberg G. Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta oncologica (Stockholm, Sweden). 2002;41(2):175–81.CrossRef
52.
Gumina MR, Xu C, Chiles TC. Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. Cell Cycle (Georgetown, Tex). 2010;9(4):820–8.CrossRef
53.
Gilmore TD, Thompson RC, Faber AC. Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. Cell Cycle (Georgetown, Tex). 2010;9(3):448–9.CrossRef
54.
Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438–51.PubMedPubMedCentralCrossRef
Metadata
Title
Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
Authors
Bo Wang
Zijian Wang
Lizhi Han
Song Gong
Yanxue Wang
Zhiwen He
Yong Feng
Zhaohui Yang
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Lymphoma
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0865-3

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Characteristics of a novel cell line ZJU-0430 established from human gallbladder carcinoma

Primary research

Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species

Primary research

Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis

Primary research

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

Primary research

Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer

Primary research

Genetic polymorphisms of estrogen receptor genes are associated with breast cancer susceptibility in Chinese women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits